On August 3, 2026 PharmaMar (MSE: PHM) reported that health authorities in Canada, Qatar and South Korea have approved Zepzelca (lurbinectedin) in combination with atezolizumab (Tecentriq) for the maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The approvals by the Canada’s Health Products and Food Branch (HPFB), the Health Qatar Ministry of Public Health (MoPH) and the Ministry of Food and Drug Safety of South Korea (MFDS) are based on the positive results from the Phase 3 IMforte[1] trial.

With these latest authorizations, the lurbinectedin–atezolizumab combination is now approved in 18 territories worldwide, including the European Union and the United States.

(Press release, PharmaMar, AUG 3, 2026, View Source [SID1234669614])